OTC · FSNUY
Healthcare · Medical - Care Facilities
$11.98
Up+$0.27 (+2.31%)
Updated Oct 10, 2026, 11:41 PM
SID Score
5.6/10
Composite research score
Smart Money
46/100
Neutral
Price performance · FSNUY
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
FSNUY closed at $11.98 after 21 trading sessions, down 8.48% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $11.98 | $12.0238 | $11.874 | $11.98 | 213.49K |
| Oct 8, 2026 | $11.63 | $11.81 | $11.6209 | $11.71 | 213.98K |
| Oct 7, 2026 | $12.27 | $12.45 | $12.045 | $12.19 | 134.73K |
| Oct 6, 2026 | $12.69 | $12.69 | $12.33 | $12.37 | 319.7K |
| Oct 5, 2026 | $12.67 | $12.67 | $12.2012 | $12.43 | 172.68K |
| Oct 2, 2026 | $12.90 | $12.90 | $12.32 | $12.425 | 2.88M |
| Oct 1, 2026 | $12.575 | $12.61 | $12.27 | $12.45 | 678.08K |
| Sep 30, 2026 | $13.44 | $13.44 | $12.641 | $12.664 | 74.88K |
| Sep 29, 2026 | $13.22 | $13.22 | $12.35 | $12.62 | 72.33K |
| Sep 28, 2026 | $13.54 | $13.54 | $13.23 | $13.35 | 131.23K |
| Sep 25, 2026 | $13.40 | $13.40 | $13.10 | $13.28 | 62.5K |
| Sep 24, 2026 | $13.16 | $13.2899 | $12.917 | $13.16 | 97.98K |
| Sep 23, 2026 | $13.1555 | $13.26 | $13.065 | $13.22 | 99.89K |
| Sep 22, 2026 | $13.20 | $13.69 | $12.92 | $13.27 | 104.18K |
| Sep 21, 2026 | $13.29 | $13.29 | $12.9216 | $13.09 | 68.08K |
| Sep 18, 2026 | $13.15 | $13.42 | $12.95 | $13.25 | 76.06K |
| Sep 17, 2026 | $13.27 | $13.2799 | $13.19 | $13.2575 | 91.57K |
| Sep 16, 2026 | $13.275 | $13.39 | $13.20 | $13.26 | 59.19K |
| Sep 15, 2026 | $13.08 | $13.17 | $12.94 | $13.13 | 108.61K |
| Sep 14, 2026 | $13.1545 | $13.27 | $12.93 | $13.22 | 151.69K |
| Sep 11, 2026 | $13.23 | $13.312 | $13.034 | $13.09 | 70.94K |
The latest Smart Investors Daily articles mentioning FSNUY.
Company
Market Activity
Research & News
FSNUY research
Company profile and research snapshot.
FRESENIUS SE S/ADR
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 21, 2026 | BERENBERG | Buy | — |
| Sep 21, 2026 | DAY BY DAY | Buy | — |
| Sep 4, 2026 | ODDO BHF | Buy | — |
| Aug 31, 2026 | BNP PARIBAS | Outperform | — |
| Aug 28, 2026 | METZLER EQUITIES | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 6, 2026
IRVING, Texas, October 06, 2026--Vizient® announced today expanded supply assurance for critical IV fluids with the addition of Fresenius Kabi to the Vizient Reserve Program.
Yahoo · Oct 1, 2026
mAbxience today announced that Fresenius SE & Co. KGaA has acquired the remaining 45% of mAbxience from Insud Pharma, building on the successful partnership established between the two companies in 2022 and marking the beginning of a new phase of growth for the company.
Yahoo · Sep 30, 2026
LAKE ZURICH, Ill., September 30, 2026--Fresenius Kabi, part of the global healthcare company Fresenius, was awarded the 2026 Pharmacy Strategic Programs Excellence Award by Vizient®, the nation’s largest provider-driven healthcare performance improvement company.
Yahoo · Sep 29, 2026
Waltz Health®, an EVERSANA® company developing technologies and services that support better-informed decisions on prescription care and Fresenius Kabi®, an operating company of Fresenius, and a leading provider of essential medicines and medical technologies, today announced an agreement to provide employers, payers and pharmacy benefit managers (PBMs) with direct access to three competitively priced biosimilars.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning FSNUY.
